Salivary Nerve and Muscle Biopsy

Beyond skin biopsy with IENFD, several specialized tissue biopsies have specific roles in neurologic diagnosis: minor salivary gland biopsy for Sjögren syndrome, nerve biopsy for vasculitic and infiltrative neuropathies, muscle biopsy for inflammatory and metabolic myopathies, temporal artery biopsy for giant cell arteritis, and brain biopsy in rare specific situations. With the explosion in genetic testing, antibody panels, MRI, and metabolic studies, the role of invasive tissue diagnosis has narrowed but remains essential in selected cases. This page covers the major specialized biopsies, indications, technique considerations, and how to integrate them into the neurologic workup.

Minor Salivary Gland Biopsy — Sjögren Syndrome

Procedure

• Biopsy of labial salivary glands (lower lip), 4-6 glands.
• Minor outpatient procedure under local anesthesia.
• Minimal scarring; minor numbness typically resolves.

Histopathologic Findings

• Focal lymphocytic sialadenitis: aggregates of ≥50 lymphocytes (focus) per 4 mm² of glandular tissue.
• Focus score ≥1 per 4 mm² supports Sjögren diagnosis.

2016 ACR/EULAR Sjögren Criteria — Salivary Biopsy as Key Component

• Salivary gland biopsy positive (focus score ≥1): 3 points.
• Anti-SSA (Ro) positive: 3 points.
• Ocular staining score ≥5: 1 point.
• Schirmer test ≤5 mm/5 min: 1 point.
• Unstimulated whole salivary flow ≤0.1 mL/min: 1 point.
• Total ≥4 points = Sjögren syndrome.

When Salivary Biopsy Is Especially Useful

• Anti-SSA-negative patients with clinical features suggestive of Sjögren.
• Neurologic-predominant Sjögren (peripheral neuropathy, CNS involvement) with equivocal serology.
• Cases where confident Sjögren diagnosis affects management (immunosuppression).

Neurologic Manifestations Diagnosed via Sjögren Workup

• Sensory ganglionopathy (non-length-dependent sensory neuropathy).
• Small fiber neuropathy.
• Length-dependent polyneuropathy.
• Optic neuritis, NMOSD (some patients with anti-AQP4).
• Cognitive dysfunction.

Sural Nerve Biopsy

Indications (Narrow in Modern Practice)

• Suspected vasculitic neuropathy: especially when serology negative or when systemic vasculitis workup unrevealing — direct demonstration of vasculitis can establish diagnosis.
• Suspected amyloidosis when noninvasive screening (SPEP, free light chains, TTR sequencing, cardiac biomarkers, fat pad biopsy) inconclusive.
• Suspected sarcoidosis neuropathy.
• Suspected leprosy neuropathy.
• Unexplained progressive neuropathy after extensive workup, in specific situations.

Procedure

• Sural nerve at the ankle (often a fascicular biopsy, leaving most fibers intact).
• Sensory loss in lateral foot is expected post-procedure (mostly tolerated but permanent).
• Specialized handling: fixed for light microscopy, electron microscopy, immunofluorescence.

Diagnostic Yield by Indication

• Vasculitic neuropathy: high yield (~60-80% when suspected on clinical grounds).
• Amyloid neuropathy: variable (deposits may be patchy).
• Hereditary neuropathies: largely supplanted by genetic testing.
• Chronic idiopathic neuropathy: usually low-yield.

Combined Nerve + Muscle Biopsy for Vasculitis

• Some labs combine sural nerve + nearby muscle (often peroneal nerve + peroneus brevis muscle).
• Increases yield for vasculitis (muscle may show vasculitis when nerve does not).

Muscle Biopsy

Indications

• Inflammatory myopathies: dermatomyositis, polymyositis, inclusion body myositis, immune-mediated necrotizing myopathy.
• Suspected metabolic myopathies: glycogen storage diseases, mitochondrial myopathies.
• Dystrophinopathies: increasingly replaced by genetic testing, but biopsy still useful in some scenarios.
• Unexplained myopathy after biochemical workup (CK, aldolase, ESR, autoantibodies).

Site Selection

• Affected but not end-stage muscle.
• Common sites: vastus lateralis, biceps brachii, deltoid.
• MRI muscle imaging can guide biopsy to affected area.

Specialized Stains and Studies

• H&E, modified Gomori trichrome, ATPase, NADH, COX, SDH — for general muscle pathology.
• Inflammatory markers (CD4, CD8, MHC-I, MAC).
• Electron microscopy.
• Western blot for dystrophin (Duchenne / Becker).
• Immunostains for sarcoglycans, dysferlin, etc., for limb girdle dystrophies (often supplanted by genetic testing).
• Mitochondrial enzyme histochemistry (ragged red fibers in mitochondrial disease).
• Acid phosphatase (lysosomal storage).

Inflammatory Myopathy Patterns

• Dermatomyositis: perifascicular atrophy, perivascular inflammation, complement deposition on capillaries, MxA expression.
• Polymyositis: endomysial CD8+ T-cell infiltrate, MHC-I upregulation.
• Inclusion body myositis: endomysial inflammation + rimmed vacuoles + protein aggregates.
• Immune-mediated necrotizing myopathy: prominent necrosis, scant inflammation, complement deposition; anti-SRP or anti-HMGCR antibodies often positive.

Temporal Artery Biopsy — Giant Cell Arteritis (GCA)

Modern Diagnostic Pathway

Patients with suspected GCA should undergo prompt diagnostic confirmation with temporal artery ultrasound or temporal artery biopsy, depending on local expertise and pathway availability. Where high-quality vascular ultrasound is available, the 2018 EULAR (and 2023 update) imaging recommendations support ultrasound as first-line. Biopsy remains important where ultrasound expertise is limited, when imaging is equivocal, or when tissue confirmation is needed. Steroids should not be delayed when vision is threatened — biopsy can remain positive 1–2 weeks after starting treatment.

When to Pursue Biopsy

• Suspected GCA based on clinical features (new headache in age >50, jaw claudication, scalp tenderness, visual loss, polymyalgia rheumatica) — especially when ultrasound is unavailable or equivocal.
• Elevated ESR / CRP supports the workup (~20% of GCA has normal ESR — don’t rule it out on labs alone).
• Whenever local expertise or pathway access favors biopsy as the primary confirmation step.

Procedure

• Local anesthesia.
• Obtain a sufficiently long specimen (commonly >1 cm, often longer in practice to reduce skip-lesion sampling risk).
• Multiple sections to find segmental inflammation.

Histopathology

• Transmural inflammation with giant cells, lymphocytes, plasma cells.
• Fragmentation of internal elastic lamina.
• Segmental (“skip lesion”) involvement.

Imaging Alternatives (Now Often First-Line)

• Temporal artery ultrasound (halo sign, compression sign): first-line in many systems where appropriate expertise exists.
• MRA / CTA / FDG-PET: for large-vessel GCA involvement (aortic / extracranial); guides systemic therapy.

Brain Biopsy

Very Limited Indications

• CNS vasculitis (primary angiitis of CNS): when diagnosis cannot be made noninvasively and clinical course warrants confirmation.
• Suspected CNS lymphoma not diagnosed by CSF cytology / flow cytometry.
• Suspected encephalitis of unclear etiology with progressive course.
• Tumor diagnosis when MRI features insufficient.

Procedure

• Stereotactic or open biopsy, often with image guidance.
• Specialized neurosurgical and neuropathology evaluation.

Caveats

• Cortical and leptomeningeal sample improves yield for vasculitis.
• Often non-diagnostic if patchy disease.
• Consider only after exhaustive noninvasive workup and when result will change management.

Fat Pad Aspirate (Amyloidosis Screen)

• Abdominal subcutaneous fat aspirate, Congo red staining.
• Less invasive than nerve / cardiac biopsy.
• Sensitivity moderate; specificity high if positive.
• Negative does not exclude amyloidosis.

Buccal Mucosa Cells, Hair, Urine — Specialized Genetic / Metabolic Tests

• Buccal swab for genetic testing.
• Skin fibroblasts for enzyme studies in suspected lysosomal storage disease (Fabry, Tay-Sachs).
• Urine for organic acid screen (suspected metabolic disorder).
• Hair for heavy metal chronic exposure assessment.

Bone Marrow Biopsy

• Indications: suspected lymphoproliferative disease driving neurologic symptoms (Waldenström macroglobulinemia, lymphoma, multiple myeloma).
• Useful in workup of anti-MAG neuropathy, POEMS syndrome.

Cardiac Biopsy / Imaging for Amyloidosis

• If TTR amyloidosis suspected (hereditary or wild-type):
  • Pyrophosphate (PYP) scintigraphy — high sensitivity/specificity for ATTR.
  • TTR gene sequencing.
  • Endomyocardial biopsy in selected cases.
• AL amyloidosis: free light chain ratio + bone marrow biopsy.

Practical Approach to Choosing the Right Biopsy

Algorithm

1. Exhaust noninvasive workup first (serology, imaging, electrodiagnostic, CSF, genetic).
2. If diagnosis remains uncertain AND result will change management → consider biopsy.
3. Choose the highest-yield tissue:
   • Sjögren suspected, serology negative → labial salivary gland.
   • Vasculitic neuropathy suspected → sural nerve + muscle.
   • Inflammatory or metabolic myopathy → muscle.
   • Giant cell arteritis suspected → temporal artery.
   • CNS vasculitis suspected, noninvasively undiagnosed → brain.
   • Amyloidosis suspected → fat pad first, then nerve / cardiac.
4. Ensure adequate specimen handling and specialized expertise (neuropathology, neuromuscular pathology).

Common Pitfalls

• Inadequate specimen size (especially for temporal artery): smaller specimens reduce sensitivity.
• Wrong site selection: end-stage atrophic muscle yields non-diagnostic results.
• Inappropriate processing: muscle and nerve biopsies require specialized fixation/handling.
• Biopsy without clear clinical question: low-yield; consider whether result will affect management.
• Steroid pre-treatment: can reduce sensitivity of biopsies for inflammatory conditions.

Pitfalls and Pearls

• Labial salivary gland biopsy: focus score ≥1 supports Sjögren; useful when serology negative.
• Sural nerve biopsy: vasculitic neuropathy (high yield), amyloidosis, sarcoidosis, leprosy.
• Combined nerve + muscle biopsy: increases vasculitis yield.
• Muscle biopsy: inflammatory myopathies (DM, PM, IBM, IMNM), metabolic myopathies, mitochondrial disease.
• Inclusion body myositis: rimmed vacuoles + endomysial inflammation diagnostic.
• Dermatomyositis: perifascicular atrophy + MxA expression.
• Temporal artery biopsy: ≥1 cm specimen; multiple sections; can be positive weeks after starting steroids.
• Don’t delay steroids in GCA: biopsy within 2 weeks acceptable.
• Brain biopsy: narrow indications; CNS vasculitis, suspected lymphoma not diagnosed otherwise.
• Fat pad aspirate: amyloidosis screen; less invasive but moderate sensitivity.
• Bone marrow biopsy: suspected lymphoproliferative drives in neuropathy.
• Pyrophosphate (PYP) scan: high sensitivity for ATTR cardiac amyloidosis.
• Genetic testing: has supplanted biopsy for most hereditary neuropathies and dystrophies.
• Specialized neuropathology expertise: essential for nerve and muscle biopsy interpretation.
• Choose biopsy when noninvasive workup is exhausted AND result will change management.
• Don’t biopsy without a clear clinical question: low yield, potential harm.

References

1. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome. Ann Rheum Dis. 2017;76(1):9-16.
2. Collins MP, Dyck PJ, Gronseth GS, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy. J Peripher Nerv Syst. 2010;15(3):176-184.
3. Salaroli R, Mazzucchelli A, Bosi M, et al. Diagnostic accuracy of temporal artery biopsy in giant cell arteritis. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S38-S43.
4. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734-1747.
5. Salvarani C, Brown RD Jr, Christianson TJH, et al. Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy. Rheumatology. 2008;47(11):1671-1677.
6. Dyck PJ, Norell JE, Tracy JA, et al. Yield and limits of nerve biopsy in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2014;19(2):126-132.
7. Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636-643 (with 2023 update).